Please wait…

Login required

Username or email:

To use this function please log-in
If you haven't got an account on, you have the opportunity to register regist here for free.

add instrument

Bellevue Funds (Lux) - BB Adamant Medtech B-EUR

Bellevue Funds (Lux) - BB Adamant Medtech B-EUR

ISIN LU0415391431 | WKN A0RP23 | Mnemonic M0U1 | Type fund
21/09/2018 14:51
Bid Ask
This product is subject to quotation restrictions.
Change from Prev. Day 0.16 EUR / 0.03%
Spread absolute / relative 6,89 / 1,49%

Net Asset Value

Previous Day 463.44 EUR Date 19/09/2018

Price Information

Last Price 462.1200
Date / Time 21.09.2018 / 14:51:31
Price -
Volume in euro -
Volume Size -
High 464.780
Low 462.120
52 week High 471.100
52 week Low 343.500
Trading Hours 09:00 - 18:00

Price History

Date Opening Price Closing Price Daily High Daily Low Volume (pcs.)
21/09/2018 464.7800 462.1200 464.7800 462.1200
20/09/2018 461.8100 461.9600 461.9600 461.7500 7
19/09/2018 461.5700 461.8100 461.8100 461.5700
18/09/2018 464.3600 461.9900 464.3600 461.9900
17/09/2018 464.1900 471.1000 471.1000 464.1900 15


Management Fee 1.60 %
Custodian Fee -
Capital forming savings possible? no
Savings Plan no
Distribution Non Distributing

Frankfurt Trading Parameters

Continous Quotation no
Minimum tradeable Unit 1

Funds Category Comparison

Name 1y perf.

Rating for Bellevue Funds (Lux) - BB Adamant Medtech B-EUR

€uro FondsNote 1
Lipper Leaders, 3 years -
Lipper Leaders, 5 years -
Lipper Leaders, 10 years -
Lipper Leaders, overall -


Fundamental Data

ISIN LU0415391431
Name Bellevue Funds (Lux) - BB Adamant Medtech B-EUR
Investment Company MDO (L)
Issued in Luxemburg
Issue Date 30/09/2009
Category Aktienfonds Pharma + Gesundheit
currency EUR
Volume -
Depositary Bank RBC Investor Services Bank S.A.
Paying Agent Bank Julius Bär
Fund Management Stefan Blum/Marcel Fritsch
Fiscal Year-End 30.06.
Last Update 15/05/2018

Investment policy

invest like Bellevue Funds (Lux) - BB Adamant Medtech B-EUR: Anlageziel ist ein langfristig attraktives und kompetitives Kapitalwachstum. Der Fonds investiert weltweit in Aktien von Unternehmen des Medizinaltechniksektors. Fokussiert werden profitable mittel- und großkapitalisierte Unternehmen, die bereits über ein reiferes Produktportfolio verfügen. Die Titelauswahl basiert auf fundamentaler Unternehmensanalyse, wobei insbesondere der medizinische Nutzen, das Sparpotenzial für das Gesundheitswesen sowie das erwartete Marktpotenzial der entsprechenden Produkte vertieft untersucht werden.

The following Disclaimer and Information has been prepared by Voltabox AG (the “Issuer”) for the purpose of publishing THE securities prospectus by the issuer. Deutsche Boerse AG does not assume any responsibility for the content of the issuer`s Disclaimer and information.


Important Information


The information contained on the following web pages is directed only at persons who are resident of or domiciled in the Federal Republic of Germany (“Germany”) or the Grand Duchy of Luxembourg (“Luxembourg”). The following information does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for any securities. No offer of securities of the Issuer is being, or will be, made to the public outside Germany and Luxembourg. The offer in Germany and Luxembourg is being made solely on the basis of the securities prospectus (including any amendments thereto) which has been approved by the German Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin) and which has been published on the Issuer’s website. Any investment decision regarding the publicly offered securities of the Issuer should only be made on the basis of the securities prospectus. The securities prospectus is available free of charge from the Issuer (Artegastraße 1, 33129 Delbrück, Germany; Tel.: +49 (0)5250 9930-900; Fax: +49 (0)5250 9762-102) and on the Issuer’s website (

The information contained on the following web pages is not an offer of securities for sale or a solicitation of an offer to purchase securities in the United States of America (“United States”), Canada, Australia or Japan. The Issuer’s shares, and the securities offered in the course of the offer, have not been and will not be registered under the US Securities Act of 1933, as amended (“Securities Act”), or with any other securities regulatory authority of any state or other jurisdiction of the United States and may not be offered, sold or delivered within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. The Issuer does not intend to register the offer or parts thereof in the United States or make an offer to the public in the United States, Canada, Australia or Japan.

The information contained on the following web pages is not for distribution to persons who are located in the United States, Canada, Australia or Japan or any other jurisdiction where the offer of the securities to the public is not taking place. Any violation of these restrictions may constitute a breach of the securities laws of these countries. The copying, forwarding or other transmission of the content of the following web pages is prohibited.

By clicking the "I AGREE" button below, you warrant that (i) you have read and accepted the foregoing information and restrictions in full and (ii) you are a resident of or domiciled in Germany or Luxembourg, and (iii) you agree not to distribute or forward the information contained on the following web pages to any person who is not a resident of or domiciled in Germany or Luxembourg.


We regret that, due to regulatory restrictions, we are unable to provide you with access to the following web pages.